Zacks: Analysts Expect DelMar Pharmaceuticals (DMPI) to Announce -$0.10 EPS

Equities research analysts expect DelMar Pharmaceuticals (NASDAQ:DMPI) to report earnings per share of ($0.10) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals reported earnings of ($0.18) per share during the same quarter last year, which indicates a positive year over year growth rate of 44.4%. The business is scheduled to issue its next earnings report on Friday, May 11th.

On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.46) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($0.26) per share. Zacks’ EPS calculations are an average based on a survey of analysts that cover DelMar Pharmaceuticals.

DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01.

Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, January 4th.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP purchased a new stake in DelMar Pharmaceuticals (NASDAQ:DMPI) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned 1.69% of DelMar Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

Shares of DelMar Pharmaceuticals stock traded up $0.03 during midday trading on Friday, reaching $1.03. The company had a trading volume of 100,629 shares, compared to its average volume of 195,185. The firm has a market cap of $22.59, a P/E ratio of -1.39 and a beta of 1.47. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $2.85.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect DelMar Pharmaceuticals (DMPI) to Announce -$0.10 EPS” was reported by Week Herald and is the property of of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply